Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Business Wire
Highlights ZW49, its HER2-Targeted Bispecific Antibody Drug Conjugate and Novel ZymeLink™ Platform VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today presented preclinical data on ZW49, its lead bispecific antibody-drug conjugate candidate (ADC) and its ZymeLink ADC platform. As previously reported, Zymeworks expects to file an Investigational New Drug (IND) application this year in order to begin clinical trials with ZW49 for patients with HER2-expressing cancers. Abstract Number: 3914; ZW49, A HER2 Targeted Biparatopic Antibody Drug Conjugate for the Treatment of HER2 Expressing Cancers Summary: ZW49, which incorporates Zymeworks’ Azymetric™ bispecific and ZymeLink™ ADC technology platforms, was shown to be active and well tolerated in a series of preclinical studies. T
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME GlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEPR Newswire
- ATTENTION ZYME SHAREHOLDERS: Investors who lost money on Zymeworks Inc. are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire
- Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data [Seeking Alpha]Seeking Alpha
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME Accesswire
ZYME
Earnings
- 3/6/24 - Beat
ZYME
Sec Filings
- 4/4/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 3
- ZYME's page on the SEC website